Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) Operating Expenses (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Operating Expenses for 2 consecutive years, with $23.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 1.23% to $23.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $109.0 million, a N/A change, with the full-year FY2024 number at $105.6 million, up 28.48% from a year prior.
  • Operating Expenses was $23.5 million for Q3 2025 at Pyxis Oncology, up from $22.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $40.1 million in Q4 2024 to a low of $20.0 million in Q2 2024.